IKNA vs. ATYR, IMMP, OLMA, KRRO, NMRA, YMAB, KOD, TVGN, NGNE, and ACIU
Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), Korro Bio (KRRO), Neumora Therapeutics (NMRA), Y-mAbs Therapeutics (YMAB), Kodiak Sciences (KOD), Tevogen Bio (TVGN), Neurogene (NGNE), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry.
Ikena Oncology vs.
Ikena Oncology (NASDAQ:IKNA) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings.
Ikena Oncology has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
In the previous week, Atyr PHARMA had 13 more articles in the media than Ikena Oncology. MarketBeat recorded 14 mentions for Atyr PHARMA and 1 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 1.88 beat Atyr PHARMA's score of 0.97 indicating that Ikena Oncology is being referred to more favorably in the media.
Ikena Oncology's return on equity of -36.88% beat Atyr PHARMA's return on equity.
75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 5.9% of Ikena Oncology shares are owned by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ikena Oncology presently has a consensus price target of $3.00, indicating a potential upside of 115.83%. Atyr PHARMA has a consensus price target of $18.60, indicating a potential upside of 330.56%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than Ikena Oncology.
Atyr PHARMA has lower revenue, but higher earnings than Ikena Oncology. Atyr PHARMA is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks.
Ikena Oncology received 18 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote.
Summary
Atyr PHARMA beats Ikena Oncology on 10 of the 18 factors compared between the two stocks.
Get Ikena Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ikena Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:IKNA) was last updated on 2/22/2025 by MarketBeat.com Staff